Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatments for hepatitis B.

David M Asmuth1, Hien H Nguyen, Gregory P Melcher

  • 1Division of Infectious Diseases, Dept. of Internal Medicine, UC Davis Medical Center, 4150 V St., PSSB G500, Sacramento, CA 95817 , USA. david.asmuth@ucdmc.ucdavis.edu

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|October 21, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission.

Critical care medicine·2026
Same author

Fosmanogepix treatment for coccidioidomycosis under an expanded access program.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Ensitrelvir for the treatment of hospitalized adults with COVID-19: an international phase 3 randomized placebo-controlled trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

An approach to Candidozyma auris surveillance in a low prevalence setting.

American journal of infection control·2025
Same author

Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection.

The Journal of infectious diseases·2025

New treatments offer hope for chronic hepatitis B (CHB) patients, with ongoing research into novel therapies and combination treatments. Challenges like drug resistance and defining treatment response require further investigation for effective CHB management.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B (CHB) is a progressive liver disease affecting many patients worldwide.
  • Current FDA-approved treatments include interferon-alpha, lamivudine, and adefovir dipivoxil, each with distinct profiles.
  • Significant unmet needs remain in CHB treatment, including managing drug resistance and optimizing therapy response.

Purpose of the Study:

  • To review current and emerging treatments for chronic hepatitis B.
  • To highlight the promise of new antiviral agents and combination therapies.
  • To identify key challenges in the management of CHB.

Main Methods:

  • Review of currently approved therapies for CHB.
  • Analysis of agents in clinical development for CHB.

Related Experiment Videos

  • Discussion of challenges in CHB treatment, including drug resistance and combination therapy.

    • Main Results:

    • Interferon-alpha, lamivudine, and adefovir dipivoxil are established CHB treatments with varied characteristics.
    • New antiviral agents in development show promise for improved efficacy and potentially a cure for CHB.
    • Understanding drug resistance and defining patient-specific responses are critical for advancing CHB therapy.

    Conclusions:

    • Optimism is high for new chronic hepatitis B treatments, including novel antiviral therapies.
    • Further research is essential to address drug resistance and optimize combination therapy strategies.
    • Defining treatment response in diverse patient subsets is crucial for effective chronic hepatitis B management.